Long term follow up of patients who have undergone Vivaer intranasal remodelling to enlarge narrow nasal valves

D.Brehmer¹ B.Olzowy²

1. HNO-Gemeinschaftspraxis, Goettingen + University Witten / Herdecke 2. HNO-Zentrum, Landsberg am Lech,

BACKGROUND

Weak and/or inward-bent cartilage of the nasal sidewall at the level of the internal nasal valve (INV) can produce stenosis and/or collapse of the nasal valve. This is a common cause of impaired nasal breathing and is often difficult to treat.

The Vivaer intranasal remodelling treatment is non-invasive and uses a stylus to deliver controlled and targeted radiofrequency heating to the nasal sidewall in order to gently reshape the tissues. It is an outpatient treatment administered under local anaesthesia.

In a previous study 20 patients underwent Vivaer treatment across 3 locations between October 2015 and February 2016 and the improvement in nasal breathing published in July

2016 (ref. 1). A NOSE score improvement of -41% was reported after 90 days (n=20).

This retrospective study investigates the duration of the effect of the Vivaer treatment on nasal breathing.


METHOD

16 of the original 20 patients who had undergone Vivaer across 3 locations were contacted and asked to participate in the collection of follow up data. Of those contacted 13/16 were successfully followed up.

Follow up consisted of physical examination of the treatment site and the recording of a current NOSE score. Patients were also asked about their overall experience and their satisfaction with the treatment.

RESULTS

- The average pre-treatment NOSE score of the n=13 patients was 67.7 (55-85, SD 11.0).
- The average long term improvement in NOSE score was 35.9 (-47%).
- On average patients improved by 1.5 severity classes vs baseline with a 91% (n=12/13) responder rate.
- The average difference between the NOSE scores at 30 days and at long term follow up was -7.4 points (SD 21.6).
- No serious adverse events were recorded at the time of treatment. Upon follow up there were no recorded incidents of scarring or abnormal healing.
- The average age of the Vivaer treatment at reexamination was 20 months
- 7 of the original n=20 were lost to follow up.



DISCUSSION

Vivaer intranasal remodelling can provide a durable and well tolerated non-invasive treatment for patients who are experiencing congestion due to narrowness or collapse of the internal nasal valve.

An improvement of -35.9 NOSE score points compares favourably to results achieved using conventional surgical interventions (ref.2).

REFERENCES

- First clinical experience with Vivaer intranasal remodeling treatment to enlarge collapsing or narrow nasal valve areas. Olzowy, Morski, Hellstern, Brehmer, poster presentation ERS 2016
- 2. Rhee, J.S. et al JAMA Facial Plast Surg. 2014;16(3):219-225. doi:10.1001/jamafacial.2013.2473

DISCLOSURE

Research grant from Aerin Medical Inc



